Business Context and Reporting Period
Company: Nephros, Inc. (NEPH)
Filing Type: Form 8-K (Current Report)
Date of Report: October 7, 2020
Event: Entry into a Material Definitive Agreement (Loan Agreement) with Specialty Renal Products, Inc. (SRP), a majority-owned subsidiary.
Key Financial Metrics and Transaction Details
This filing reports a specific intercompany financing arrangement rather than general operating results. Key financial terms include:
- Total Loan Commitment: Up to $1,258,555.56.
- Initial Disbursement: $758,555.56 (already funded as of the agreement date).
- Remaining Availability: Up to $500,000 upon written request.
- Interest Rate: 8.00% per annum simple interest on unpaid principal.
- Default Interest Rate: 12.00% per annum (8.00% + 4.00%) if payments are missed.
- Commitment Period Expiration: November 30, 2021, or earlier upon an Event of Default.
- Conversion Feature: Convertible into new securities if SRP raises $2,000,000 or more in a Financing Event.
Note: The filing does not provide general revenue, profit, cash flow, or margin data for Nephros, Inc. or SRP.
Material Changes and Purpose
The primary material change is the formalization of funding for SRP's hemodialysis filtration (HDF) product. The loan proceeds are designated for:
- Preparation and submission of the HDF product for FDA 510(k) clearance.
- Conducting clinical trials.
- Commercial launch activities.
Outlook, Risks, and Covenants
Covenants: The agreement includes customary affirmative covenants and negative covenants restricting SRP from merging, selling assets outside the ordinary course, changing incorporation state, or granting other security interests without consent.
Events of Default: Include failure to pay obligations, failure to perform under the agreement, bankruptcy/insolvency proceedings, or judgments against SRP exceeding $100,000 in aggregate. Upon default, the Company may demand immediate payment of all outstanding amounts.
Risks: The success of the subsidiary's product launch and FDA clearance is contingent on the availability of these funds and the successful execution of clinical trials.
Investor Verification Checklist
- Verify the status of the remaining $500,000 commitment and whether SRP has requested further disbursements.
- Review the full text of the Loan Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 10.2) for specific definitions of "Financing Event" and "Conversion Price."
- Monitor SRP's progress toward FDA 510(k) clearance for the HDF product.
- Check subsequent filings for any Events of Default or changes in the subsidiary's capital structure.